Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacokinetics of Omadacycline in Cystic Fibrosis
Sponsor: Paul Beringer
Summary
The purpose of this study is to characterize the pharmacokinetics of intravenous and oral omadacycline in patients with cystic fibrosis.
Official title: Pharmacokinetics of Omadacycline in Patients With Cystic Fibrosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
9
Start Date
2021-07-01
Completion Date
2023-12-31
Last Updated
2026-05-08
Healthy Volunteers
No
Conditions
Interventions
Omadacycline Injection [Nuzyra]
Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
Omadacycline Oral Tablet [Nuzyra]
Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
Locations (1)
University of Southern California
Los Angeles, California, United States